{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=53", "query": { "condition": "Glioblastoma, Glioma", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1352, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+Glioma&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T13:44:25.591Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04817254", "title": "Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Malignant Glioma" ], "interventions": [ { "name": "TMZ", "type": "DRUG" }, { "name": "ipilimumab 3mg/kg", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "ipilimumab 1mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-12-08", "completion_date": "2026-03-20", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04817254" }, { "nct_id": "NCT05739942", "title": "Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed and Recurrent Glioblastoma" ], "interventions": [ { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "Temozolomide", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 42, "start_date": "2024-05-15", "completion_date": "2027-08-10", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05739942" }, { "nct_id": "NCT04762069", "title": "A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme, Adult" ], "interventions": [ { "name": "Berubicin", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CNS Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-05-18", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762069" }, { "nct_id": "NCT01086345", "title": "Radiosurgery Plus Bevacizumab in Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Brain Tumor" ], "interventions": [ { "name": "radiosurgery", "type": "RADIATION" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2010-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086345" }, { "nct_id": "NCT01837862", "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pilomyxoid Astrocytoma", "Pilocytic Astrocytoma", "Glioma, Astrocytic", "Optic Nerve Glioma", "Pleomorphic Xanthoastrocytoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Gliosarcoma", "Diffuse Intrinsic Pontine Glioma", "DIPG", "Low-grade Glioma", "Brainstem Glioma" ], "interventions": [ { "name": "Mebendazole", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Krystal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 10, "start_date": "2013-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837862" }, { "nct_id": "NCT00187486", "title": "Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "Tarceva", "type": "DRUG" }, { "name": "Temodar", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2004-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00187486" }, { "nct_id": "NCT03452579", "title": "Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard Dose Bevacizumab", "type": "DRUG" }, { "name": "Low Dose Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Peereboom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2018-05-21", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cleveland, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452579" }, { "nct_id": "NCT00376818", "title": "Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" }, { "name": "management of therapy complications", "type": "OTHER" }, { "name": "mind-body intervention procedure", "type": "BEHAVIORAL" }, { "name": "Measurement of stress-related hormones", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2006-06", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376818" }, { "nct_id": "NCT00795665", "title": "Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-06", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795665" }, { "nct_id": "NCT00352521", "title": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-04", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2014-07-22", "last_synced_at": "2026-10-21T13:44:25.591Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352521" } ] }